Goldschmidt, Hartmut

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 102

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Jagannath, S., Lin, Y., Goldschmidt, H., Reece, D., Nooka, A., Senin, A., Rodriguez-Otero, P., Powles, R., Matsue, K., Shah, N., et al. (2021) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 90

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

Xu, J., Pfarr, N., Endris, V, Mai, E. K., Md Hanafiah, N. H., Lehners, N., Penzel, R., Weichert, W., Ho, A. D., Schirmacher, P., et al. (2017) · Oncogenesis

Multiple Myeloma Research and TreatmentsMelanoma and MAPK Pathways

Cited by 89

Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma

Termini, R., Žihala, D., Terpos, E., Perez-Montaña, A., Jelínek, T., Raab, M., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2022) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 54

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 50

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E-mutated multiple myeloma

Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 48

Deciphering the genetics and mechanisms of predisposition to multiple myeloma

Went, M., Duran-Lozano, L., Halldorsson, G. H., Gunnell, A., Ugidos-Damboriena, N., Law, P., Ekdahl, L., Sud, A., Thorleifsson, G., Thodberg, M., et al. (2024) · Nature Communications

Multiple Myeloma Research and TreatmentsGenetic Associations and Epidemiology

Cited by 30

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Agha, M. E., Cohen, A. D., Madduri, D., Cohen, Y. C., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., et al. (2021) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 30

Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma

Lutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology

Multiple Myeloma Research and TreatmentsBone Tumor Diagnosis and Treatments

Cited by 25

Direct evidence for a polygenic etiology in familial multiple myeloma

Halvarsson, B.-M., Wihlborg, A.-K., Ali, M., Lemonakis, K., Johnsson, E., Niroula, A., Cibulskis, C., Weinhold, N., Försti, A., Alici, E., et al. (2017) · Blood Advances

Multiple Myeloma Research and TreatmentsGenetic Associations and Epidemiology

Cited by 21

The Glycome of Normal and Malignant Plasma Cells

Moehler, T. M., Seckinger, A., Hose, D., Andrulis, M., Moreaux, J., Hielscher, T., Willhauck-Fleckenstein, M., Merling, A., Bertsch, U., Jauch, A., et al. (2013) · PLoS ONE

Multiple Myeloma Research and TreatmentsGlycosylation and Glycoproteins Research

Cited by 17

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Cirrincione, A. M., Poos, A. M., Ziccheddu, B., Kaddoura, M., Bärtsch, M.-A., Maclachlan, K., Chojnacka, M., Diamond, B., John, L., Reichert, P., et al. (2024) · Blood

Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research

Cited by 15

Temporal genomic dynamics shape clinical trajectory in multiple myeloma

Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 14

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.

Einsele, H., Cohen, A. D., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., et al. (2022) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 7

P945: REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY

Ramasamy, K., Goldschmidt, H., Moreau, P., Petrucci, M.-T., Kuter, D., Durie, B., Cella, D., Dhanda, D., Gu, J., Amin, S., et al. (2023) · HemaSphere

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3

MM-464 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up

Moreau, P., Weisel, K., de Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Vincent, L., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1